GQ Bio Therapeutics Closes Collaboration Deal with Pacira BioSciences, Inc. for Development of a Commercial-Scale Manufacturing Process for High-Capacity Adenoviral Vectors. As part of the multi-million-dollar collaboration, GQ Bio will lead the process development, which will take place at GQ Bio’s R&D facility in Germany, as well as contract research organizations. While the development of the manufacturing process is initially focused on PCRX-201, GQ Bio will be able to use the process for its entire HCAd platform including the lead candidate GQ-501. Read more: http://bit.ly/44dsYkf
GQ Bio Therapeutics’ Post
More Relevant Posts
-
GQ Bio Therapeutics had the honor of hosting Ruppert Stüwe , member of the German federal parliament, and Erik Stohn, member of the Brandenburg state parliament, at our R&D facilities in Luckenwalde. We had a productive discussion about strategies to bolster the biotech sector and gene therapy companies in Germany, in particular in the greater Berlin area, including Luckenwalde.
-
-
GQ Bio Therapeutics to attend the OARSI - Osteoarthritis Research Society International World Congress (April 18 – 21 2024, Vienna)🤝🇦🇹 The OARSI World Congress is the premier annual international forum for those involved in OA research and treatment. Meet GQ Bio Therapeutics’ COO and Co-founder Stanislav Plutizki to talk about our high-capacity #genetherapy vector platform (HCAd) and its use for transformative gene therapies for prevalent diseases such as #osteoarthritis and intervertebral #discdegeneration.
-
GQ Bio Therapeutics' CEO Kilian Guse and head of bioinformatics Brian Dawson will discuss our #AI approach for capsid engineering of gene therapy vectors at the FoldForum in Hamburg April 24. Looking forward to seeing you there! https://lnkd.in/e5Ez9NFD
Medical Doctor, GP, Surgeon, Scientist, Entrepreneur, Investor, Medtech and Biotech Enthusiast
🌟 Save the Date für FoldForum # 2: Revolution der Proteinwissenschaften durch Deeptech! presented by AUFBRUCH.Hamburg 🚀 Health Panels und Artificial Intelligence Center Hamburg (ARIC)🌟 📅 Wann: 24.04.2024 um 16.00 Uhr. Du bist herzlich eingeladen, bei einem faszinierenden Abend dabei zu sein, an dem sich alles um neueste Deeptech-Entwicklungen in den Proteinwissenschaften dreht. Wo: DeepTech Campus (für Details siehe LinkedIn Veranstaltung) 🔬 Moderation: Natalie Rotermund und Dr. Dr. Alexander T. El Gammal (MD, PhD) 🗣 Speaker: Kilian Guse (CEO, GQ Bio Therapeutics), Prof. Dr. Jens Bosse, Dr. Felix Tobola, und Jakob Mertes (Machine Learning Engineer, ARIC) 🚀 Lasst Euch inspirieren von den führenden Köpfen in Biotechnologie, KI-Engineering im Bereich Proteomics und entdecke, wie Innovationen die Grenzen des Möglichen neu definieren. 👥 Perfekt für Netzwerker und Innovationsenthusiasten! Trefft Experten und Gleichgesinnten aus der DeepTech- Branche. 🎟 Registrierung: Kostenlos! Melde dich über den Eventim-Link in der LinkedIn Veranstaltung an und sichere dir deinen Platz. #FoldForum #ProteinScience #Deeptech #Biotech #AI #Networking #Innovation #AUFBRUCHHamburg #ARIC 🔗🔬🧬 Verpasse nicht die Chance, Teil dieser zukunftsweisenden Veranstaltung zu sein!
This content isn’t available here
Access this content and more in the LinkedIn app
-
Congratulations to the Pacira BioSciences, Inc. team for receiving RMAT designation for PCRX-201! This is a great achievement as the RMAT designation was based on strong clinical data in knee #osteoarthritis patients and can expedite the further development of PCRX-201, which was originally developed by GQ Bio Therapeutics. Also, PCRX-201 marks the first-ever #genetherapy to receive RMAT designation – a significant step forward for the high-capacity adenoviral vector technology! https://lnkd.in/dSyb283Y
-
